©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 10, 2015; 6(7): 970-977
Published online Jul 10, 2015. doi: 10.4239/wjd.v6.i7.970
Published online Jul 10, 2015. doi: 10.4239/wjd.v6.i7.970
Dyslipidaemia of diabetes and the intestine
Gerald H Tomkin, Daphne Owens, Beacon Hospital Sandyford and Trinity College, Dublin 2, Ireland
Author contributions: Both authors contributed to this manuscript.
Conflict-of-interest statement: Neither Gerald H Tomkin nor Daphne Owens has any conflict of interest.
Correspondence to: Gerald H Tomkin, Professor, Beacon Hospital Sandyford and Trinity College, Clontra, Quinns Road, Shankill, Co Dublin, Dublin 2, Ireland. gerald.tomkin@tcd.ie
Telephone: +353-1-2390658 Fax: +353-1-2721395
Received: September 12, 2014
Peer-review started: September 13, 2014
First decision: December 12, 2014
Revised: February 11, 2015
Accepted: March 5, 2015
Article in press: March 9, 2015
Published online: July 10, 2015
Processing time: 300 Days and 19 Hours
Peer-review started: September 13, 2014
First decision: December 12, 2014
Revised: February 11, 2015
Accepted: March 5, 2015
Article in press: March 9, 2015
Published online: July 10, 2015
Processing time: 300 Days and 19 Hours
Core Tip
Core tip: The explosion of type 2 diabetes has generated increasing interest on the aetiology of atherosclerosis in diabetic patients. Evidence is mounting on the importance of the atherogenic properties of triglyceride rich lipoproteins. In the post-prandial phase 50% of triglyceride rich lipoproteins come from chylomicrons produced in the intestine. Recent evidence has secured the chylomicron as a major player in the atherogenic process. In diabetes chylomicron production is increased through disturbance in cholesterol absorption. This paper reviews recent literature in relation to diabetes, the intestine and dyslipidaemia with a view to understanding new targets for treatment.